AngioLogix
Stage
Series A | AliveTotal Raised
$1.8MLast Raised
$1.8M | 13 yrs agoMissing: AngioLogix's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: AngioLogix's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
AngioLogix Patents
AngioLogix has filed 2 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
10/4/2011 | 2/25/2014 | Diabetes, Cardiology, Angiology, Medical terminology, Measurement | Grant |
Application Date | 10/4/2011 |
|---|---|
Grant Date | 2/25/2014 |
Title | |
Related Topics | Diabetes, Cardiology, Angiology, Medical terminology, Measurement |
Status | Grant |
AngioLogix Frequently Asked Questions (FAQ)
Where is AngioLogix's headquarters?
AngioLogix's headquarters is located at 1793 San Ramon Ave, Mountain View.
What is AngioLogix's latest funding round?
AngioLogix's latest funding round is Series A.
How much did AngioLogix raise?
AngioLogix raised a total of $1.8M.
Who are the investors of AngioLogix?
Investors of AngioLogix include Wharton Venture Initiation Program.
Who are AngioLogix's competitors?
Competitors of AngioLogix include Affidea, Biodesix, Signature Diagnostics, Pathwork Diagnostics, Cylex and 11 more.
Compare AngioLogix to Competitors
ProteoGenix offers maternal-fetal diagnostics
LabNow has developed the LabNow System to conduct healthcare-related diagnostics at the point-of-care.
Hx Diagnostics offers rapid diagnostics for seasonal and emerging infectious diseases.
XDx is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive gene expression testing in the areas of transplant medicine and autoimmunity. Per the company, they have developed a proprietary method of utilizing gene expression in blood that aims to provide a new tool for physicians to manage the care of heart transplant patients. The molecular expression technology developed and implemented by XDx in heart transplant patient management is currently being explored to assist with other diseases that involve the immune system.
Ativa Medical is a medical diagnostics company that is working to make diagnostic test results available in moments, rather than hours and days.
Cleveland Biosensors produces the BioFiniti Point-Of-Care diagnostics system - rapid, quantitative, portable instruments using disposable microfluidic cartridges.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.